Although the performance of our method in the Validation set was not high enough to corroborate the use as a single diagnostic clinical test, we showed that it could be used as a complement for the two main routinely used biomarkers (CA-125 and HE4) in the diagnosis of early stage ovarian cancer (miRNA-based model AUC = 0.789; miRNA/protein-based model AUC = 1.000). The gene discussed is MUC16; the disease is ovarian carcinoma.